吉西他滨联合顺铂序贯吉非替尼治疗晚期非小细胞肺癌  

A Clinical Study on Gemcitabin Combined With cisplatin sequential to Gefitinib in the Treatment of Advanced Non- small Cell Lung Cancer

作　　者：过雪丹[1] 吴福林[1] 陈暑波[1] 徐伟[1] 黄庆[2] 

机构地区：[1]无锡市第二人民医院肿瘤科,江苏无锡214002 [2]无锡市人民医院内科,江苏无锡214002

出　　处：《现代生物医学进展》2012年第9期1696-1698,共3页Progress in Modern Biomedicine

摘　　要：目的:观察吉西他滨联合顺铂序贯吉非替尼治疗晚期非小细胞肺癌的疗效与毒副反应。方法:71例经病理学诊断的晚期(Ⅲb-Ⅳ期)非小细胞肺癌患者,随机分成两组,观察组给予吉西他滨加顺铂化疗,序贯吉非替尼。对照组给予吉西他滨加顺铂化疗。结果:两组有效率(RR)为36.1%VS14.3%(P=0.0362);疾病控制率(DCR)比较x2=14.782,P<0.001;中位生存期(MST)为12.1月VS10.8月(P<0.05);有统计学差异;观察组除了皮疹、腹泻毒副反应较大外,其他与对照组相仿。结论:吉西他滨联合顺铂序贯吉非替尼治疗晚期非小细胞肺癌有较好的疗效和安全性,可以扩大样本继续观察。Objective：To study with the clinical efficacy and toxicity for adcanced no-small cell lung cancer using Gemcitabin Combined With cisplatin sequential to Gefitinib rigemen.Methods： 54 cases with pathological dignosis of advanced no-small cell lung cancer（Ⅲb-Ⅳ） were divided stochastically into gemcitabin combined with cisplatin followed by gefitinib treatment group and gemcitabin combined with cisplatin group.Results： In 71 cases,the overall response rates（RR） of two groups were 36.1%VS14.3%（P=0.0362）;The DCR of two groups were 83.3% VS42.9%（x2=14.782,P〈0.001）;The median survial time（MST） was 12.1months and 10.8months respectively（P〈0.05）;There’s no statistics difference between two groups but rash and diarrhea.Conclusion： Good clinical efficacy and safety were achieved in the therapy of adcanced no-small cell lung cancer using Gemcitabin Combined With cisplatin sequential to Gefitinib rigemen.It is worthy of further enlarged sample research.

关 键 词：吉西他滨 顺铂 吉非替尼 序贯 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]